Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER

Trial Profile

A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer; Squamous cell cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOTALA
  • Sponsors Pfizer

Most Recent Events

  • 03 Oct 2023 Results published in the Oncologist
  • 08 Jun 2021 Results of a biomarker analysis assessing tumor BRCA mutational status and zygosity and overall mutational landscape in patients treated with Talazoparib for whom biomarker results are available presented at the 57th Annual Meeting of the American Society of Clinical Oncology
  • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top